on Mainz BioMed N.V.
Mainz Biomed Collaborates with Thermo Fisher for Cancer Screening Development
Mainz Biomed N.V. has announced a collaboration with Thermo Fisher Scientific to develop next-generation colorectal cancer screening products. This partnership will leverage Thermo Fisher's technology to enhance Mainz Biomed's mRNA-based screening tests. These tests aim to improve early detection of colorectal cancer and precancerous lesions, showcasing promising results in trials across the US and Europe.
This collaboration will focus on developing proprietary assays at Mainz Biomed’s labs in Germany. Guido Baechler, CEO of Mainz Biomed, highlighted the potential for a home collection screening tool, emphasizing Thermo Fisher's contribution to accelerating innovation in cancer detection.
Peter Jacobs from Thermo Fisher expressed excitement about the partnership, anticipating rapid progress in bringing new assays to the global market. This alliance aims to deliver innovative solutions for colorectal cancer screening, furthering Mainz Biomed's product development capabilities.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mainz BioMed N.V. news